FrancophonIA/ELRC3.0 huggingface dataset:
English: The mode of action of thiazides is through inhibition of the Na+Cl- symporter by competing for the Cl- site, thereby affecting electrolyte reabsorption mechanisms: directly increasing sodium and chloride excretion to an approximately equal extent, and indirectly by this diuretic action reducing plasma volume, with consequent increases in plasma renin activity, aldosterone secretion and urinary potassium loss, and a decrease in serum potassium.
Maltese: -, b'hekk jeffettwa il-mekkaniżmi li bihom jerġgħu jiġu assorbiti l-elettroliti: iżid direttament l-eskrezzjoni ta' sodium u chloride b'madwar l-istess ammont, u indirettament b'din l-azzjoni dijuretika billi jnaqqas il-volum tal-plażma, b'konsegwenza ta' żidiet fl-attività tar-renin fil-plażma, sekrezzjoni ta' aldosterone u telf tal-potassium fl-awrina tnaqqis tal-potassium fis-serum.
English: Each film-coated tablet contains 300 mg aliskiren (as hemifumarate) and 12.5 mg hydrochlorothiazide.
Maltese: Kull pillola miksija b'rita fiha 300 mg aliskiren (bħala hemifumarate) u 12.5 mg hydrochlorothiazide.
English: Erythema multiforme Musculoskeletal and connective tissue disorders Not known:
Maltese: Eritema multiformi Disturbi muskolu-skeletriċi u tat-tessuti konnettivi
English: Each film-coated tablet contains 150 mg aliskiren (as hemifumarate) and 12.5 mg hydrochlorothiazide.
Maltese: Kull pillola miksija b'rita fiha 150 mg aliskiren (bħala hemifumarate) u 12.5 mg hydrochlorothiazide.
English: Film-coated tablet
Maltese: • Spażmi fil-muskoli
English: If hypokalaemia develops during hydrochlorothiazide therapy Riprazo HCT should be discontinued until stable correction of the potassium balance.
Maltese: Jekk l-ipokalimja tiżviluppa waqt it-terapija b'hydrochlorothiazide Riprazo HCT għandu jitwaqqaf sakemm ikun hemm stabilità korretta fil- bilanċ tal-potassju.
English: - Each Riprazo HCT 300 mg/12.5 mg film-coated tablet contains 300 mg aliskiren (as hemifumarate) and 12.5 mg hydrocholorothiazide.
Maltese: Kull pillola miksija b'rita ta' Riprazo HCT 300 mg/12.5 mg fiha 300 mg aliskiren (bħala ilhemifumarate) u 12.5 mg hydrochlorothiazide.
English: Co-administration with aliskiren 150 mg resulted in a 61% decrease in aliskiren AUC and co-administration with aliskiren 300 mg resulted in a 38% decrease in aliskiren AUC.
Maltese: L-għoti tiegħu flimkien ma' aliskiren 150 mg wassal għal tnaqqis ta' 61% fl-AUC ta' aliskiren u l-għoti flimkien ma' aliskiren 300 mg wassal għal tnaqqis ta' 38% fl-AUC ta' aliskiren.
English: Riprazo HCT has been shown to be effective as a once-a-day antihypertensive treatment in adult patients, regardless of gender, age, body mass index and ethnicity.
Maltese: Riprazo HCT intwera li huwa effettiv bħala kura li tingħata darba kuljum kontra l-pressjoni għolja f'pazjenti aduti, ikun x'ikun is-sess, l-età, l-indiċi tal-massa tal-ġisem u l-etniċità.
English: FOLDING BOX FOR UNIT PACK CONTAINING PVC/PCTFE BLISTERS
Maltese: FIH FOLJI TAL-PVC/PCTFE
English: You should not take Riprazo HCT together with grapefruit juice.
Maltese: M'għandekx tieħu Riprazo HCT mal-meraq tal-grejpfrut.
English: Each film-coated tablet contains 300 mg aliskiren (as hemifumarate) and 25 mg hydrochlorothiazide.
Maltese: Kull pillola miksija b'rita fiha 300 mg aliskiren (bħala hemifumarate) u 25 mg hydrochlorothiazide.
English: EU/1/11/680/030 EU/1/11/680/031 EU/1/11/680/032 EU/1/11/680/033 EU/1/11/680/034 EU/1/11/680/035 EU/1/11/680/036
Maltese: EU/1/11/680/031 EU/1/11/680/032 EU/1/11/680/033 EU/1/11/680/034
English: EU/1/11/680/001 EU/1/11/680/002 EU/1/11/680/003 EU/1/11/680/004 EU/1/11/680/005 EU/1/11/680/006
Maltese: EU/1/11/680/001 EU/1/11/680/002 EU/1/11/680/003 EU/1/11/680/004
English: EU/1/11/680/061 EU/1/11/680/062 EU/1/11/680/063 EU/1/11/680/064 EU/1/11/680/065 EU/1/11/680/066
Maltese: EU/1/11/680/061 EU/1/11/680/062 EU/1/11/680/063 EU/1/11/680/064
English: Each film-coated tablet contains 150 mg aliskiren (as hemifumarate) and 25 mg hydrochlorothiazide.
Maltese: Kull pillola miksija b'rita fiha 150 mg aliskiren (bħala hemifumarate) u 25 mg hydrochlorothiazide.
English: Riprazo HCT 300 mg /25 mg may be administered in patients whose blood pressure is not adequately controlled with aliskiren 300 mg or hydrochlorothiazide 25 mg alone or by Riprazo HCT 300 mg/12.5 mg or Riprazo HCT 150 mg/25 mg.
Maltese: Riprazo HCT 300 mg/25 mg jista' jingħata f'pazjenti li jkollhom il-pressjoni tad-demm li ma tkunx ikkontrollata kif jixraq b'aliskiren 300 mg jew hydrochlorothiazide 25 mg waħidhom jew b'Riprazo HCT 300 mg/12.5 mg jew b'Riprazo HCT 150 mg/25 mg.
English: What Riprazo HCT looks like and contents of the pack Riprazo HCT 150 mg/12.5 mg film-coated tablets are white, oval film-coated tablets imprinted with “LCI” on one side and “NVR” on the other.
Maltese: Id-Dehra ta' Riprazo HCT u l-kontenuti tal-pakkett Riprazo HCT 150 mg/12.5 mg pilloli miksijin b'rita huma pilloli miksijin b'rita bojod, ovali stampati b' “LCI” fuq naħa u “NVR” fuq l-oħra.
English: Lithium: Renal clearance of lithium is reduced by thiazides, therefore the risk of lithium toxicity may be increased with hydrochlorothiazide.
Maltese: L-eliminazzjoni ta' lithium mill-kliewi titnaqqas mit-thiazides, għalhekk ir-riskju ta' tossiċità b'lithium tiżdied b'hydrochlorothiazide.
English: EU/1/11/680/041 EU/1/11/680/042 EU/1/11/680/043 EU/1/11/680/044 EU/1/11/680/045 EU/1/11/680/046
Maltese: EU/1/11/680/042 EU/1/11/680/043 EU/1/11/680/044
English: Organic anion transporting polypeptide (OATP) inhibitors: Preclinical studies indicate that aliskiren might be a substrate of organic anion transporting polypeptides.
Maltese: Studji prekliniċi juru li aliskiren jista' jkun sustanza ta' pompa organika ta' esportazzjoni anjonika.
English: EU/1/11/680/010 EU/1/11/680/011 EU/1/11/680/012 EU/1/11/680/013 EU/1/11/680/014 EU/1/11/680/015 EU/1/11/680/016
Maltese: EU/1/11/680/011 EU/1/11/680/012 EU/1/11/680/013 EU/1/11/680/014
English: Other inducers of P-gp (St. John's wort) might decrease the bioavailability of aliskiren.
Maltese: John's Wort) jistgħu jnaqqsu l-bijodisponibilità ta' aliskiren.
English: Renal dysfunction, acute renal failure Reproductive system and breast disorders Common:
Maltese: Disfunzjoni fil-kliewi, indeboliment sever tal-kliewi Disturbi fis-sistema riproduttiva u fis-sider Komuni:
English: Asthenia, pyrexia
Maltese: • Skonfort fiż-żaqq
English: Riprazo HCT 150 mg/25 mg film-coated tablets
Maltese: Riprazo HCT 150 mg/25 mg pilloli miksijin b'rita
English: Hypersensitivity to the active substances or to any of the excipients (see section 6.1), or to other sulphonamide-derived substances.
Maltese: Sensittività eċċessiva għas-sustanzi attivi jew għal xi sustanzi mhux attivi (ara sezzjoni 6.1), jew għal xi derivati oħrajn ta' sulphonamide.
English: In post-marketing experience, renal dysfunction and cases of acute renal failure have been reported in patients at risk (see section 4.4).
Maltese: Fl-esperjenza ta' wara t-tqegħid fis-suq, kliewi li ma jaħdmux tajjeb u każi ta' insuffiċjenza akuta talkliewi kienu rrappurtati f'pazjenti li kienu f'riskju (ara sezzjoni 4.4).
English: The concomitant use of aliskiren with ARBs or ACEIs is contraindicated in patients with diabetes mellitus or renal impairment (GFR < 60 ml/min/1.73 m2) (see sections 4.2, 4.4, 4.5 and
Maltese: L-użu ta' aliskiren ma' ARBs jew ACEIs huwa kontra-indikat f'pazjenti b'dijabete mellitus jew b'indeboliment renali (GFR < 60 ml/min/1.73 m2) u mhuwiex rakkomandat f'pazjenti oħra (ara sezzjonijiet 4.3, 4.4 u
English: The concomitant use of Riprazo HCT with angiotensin II receptor blockers (ARB) or angiotensin converting enzyme inhibitors (ACEI) is contraindicated in patients with renal impairment (GFR < 60 ml/min/1.73 m2) (see sections 4.3, 4.4 and 5.2).
Maltese: L-użu ta' aliskiren ma' ARBs jew ACEIs huwa kontra-indikat f'pazjenti b'dijabete mellitus jew b'indeboliment renali (GFR < 60 ml/min/1.73 m2) u mhuwiex rakkomandat f'pazjenti oħra (ara sezzjonijiet 4.3, 4.4 u 5.1).
English: Riprazo HCT 300 mg/25 mg film-coated tablets
Maltese: Riprazo HCT 300 mg/25 mg pilloli miksijin b'rita
English: Riprazo HCT 150 mg /25 mg may be administered in patients whose blood pressure is not adequately controlled with aliskiren 150 mg or hydrochlorothiazide 25 mg alone or by Riprazo HCT 150 mg/12.5 mg.
Maltese: Riprazo HCT 150 mg/25 mg jista' jingħata f'pazjenti li jkollhom il-pressjoni tad-demm li ma tkunx ikkontrollata kif jixraq b'aliskiren 150 mg jew hydrochlorothiazide 25 mg waħidhom jew b'Riprazo HCT 150 mg/12.5 mg.
English: The concomitant use of aliskiren and ACEIs or ARBs is contraindicated in patients with diabetes mellitus or renal impairment (GFR < 60 ml/min/1.73 m2) (see sections 4.3, 4.5
Maltese: L-użu konkomitanti ta' aliskiren u ACEIs jew ARBs huwa kontra-indikat f'pazjenti b'dijabete mellitus jew b'indeboliment renali (GFR < 60 ml/min/1.73 m2) (ara sezzjonijiet 4.3, 4.5 u 4.8).
English: FOLDING BOX FOR UNIT PACK CONTAINING PA/ALU/PVC BLISTERS
Maltese: KAXXA LI TINTLEWA GĦALL-PAKKETT B'WIEĦED LI FIH FOLJI PA/ALU/PVC
English: Riprazo HCT 150 mg/12.5 mg film-coated tablets
Maltese: Riprazo HCT 150 mg/12.5 mg pilloli miksijin b'rita
English: Riprazo HCT 300 mg /12.5 mg may be administered in patients whose blood pressure is not adequately controlled with aliskiren 300 mg or hydrochlorothiazide 12.5 mg alone or by Riprazo HCT 150 mg/12.5 mg.
Maltese: Riprazo HCT 300 mg/12.5 mg jista' jingħata f'pazjenti li jkollhom il-pressjoni tad-demm li ma tkunx ikkontrollata kif jixraq b'aliskiren 300 mg jew hydrochlorothiazide 12.5 mg waħidhom jew b'Riprazo HCT 150 mg/12.5 mg.
English: Cytotoxic agents: Thiazides, including hydrochlorothiazide, may reduce the renal excretion of cytotoxic agents (e.g. cyclophosphamide, methotrexate) and potentiate their myelosuppressive effects.
Maltese: It-thiazides, inkluż hydrochlorthiazide, jistgħu jnaqqsu t-tneħħija renali ta' sustanzi ċitotossiċi (eż. ċiklofosfamid, methotrexate) u jsaħħu l-effetti majelosoppressivi tagħhom.
English: For convenience, patients receiving aliskiren and hydrochlorothiazide from separate tablets may be switched to a fixed combination tablet of Riprazo HCT containing the same component doses.
Maltese: Għall-konvenjenza, pazjenti li jkunu qed jirċievu aliskiren u hydrochlorothiazide minn pilloli separati jistgħu jinqalbu għall-pillola ta' taħlita fissa ta' Riprazo HCT li fiha l-istess dożi tal-komponenti.
English: Riprazo HCT 300 mg/25 mg film-coated tablets are light yellow, oval film-coated tablets imprinted with “CVV” on one side and “NVR” on the other.
Maltese: Riprazo HCT 300 mg/25 mg pilloli miksijin b'rita huma pilloli miksijin b'rita sofor ċari, ovali stampati b' “CVV” fuq naħa u “NVR” fuq l-oħra.
English: No adjustment of the initial dose is required for patients with mild to moderate hepatic impairment (see section 5.2).
Maltese: Mhux meħtieġ li jkun hemm aġġustar tad-doża f'pazjenti b'indeboliment epatiku ħafif għal moderat (ara sezzjoni 5.2).
English: Medicinal products that could induce torsades de pointes: Due to the risk of hypokalaemia, hydrochlorothiazide should be administered with caution when associated with medicinal products that could induce torsades de pointes, in particular Class Ia and Class III antiarrhythmics and some antipsychotics.
Maltese: Minħabba r-riskju ta' ipokalimja, hydrochlorothiazide għandu jingħata b'kawtela meta jkun assoċjat flimkien ma' prodotti mediċinali li jistgħu jwasslu għal torsades de pointes, b'mod partikulari antiirrittmiċi ta' Klassi
English: Upon withdrawal of the aliskiren treatment (aliskiren with or without hydrochlorothiazide add-on), the return of blood pressure towards baseline was gradual (3-4 weeks) with no evidence of the rebound effect.
Maltese: Meta twaqqfet il-kura b'aliskiren (aliskiren b'hydrochlorothiazide jew mingħajru miżjud), il-pressjoni tad-demm marret lura ghal-linja bażi b'mod gradwali (3-4 ġimgħat) mingħajr ma deher ebda effett rebound.
English: Gastrointestinal disorders Common:
Maltese: Disturbi gastro-intestinali
English: OUTER CARTON OF MULTIPACKS (INCLUDING BLUE BOX) CONTAINING PA/ALU/PVC BLISTERS
Maltese: (INKLUŻA L-KAXXA Ċ-ĊELESTI) LI JKUN FIHA L-FOLJI PA/ALU/PVC
English: In the event of any signs suggesting a hypersensitivity reaction/angioedema (in particular difficulties in breathing or swallowing, rash, itching, hives or swelling of the face, extremities, eyes, lips and/or tongue, dizziness) patients should discontinue treatment and contact the physician (see section 4.4).
Maltese: Każijiet ta' anġjoedima jew sintomi li jissuġġerixxu anġjoedima (nefħa fil-wiċċ, fix-xofftejn, filgerżuma u/jew fl-ilsien) kienu wkoll irrappurtati fl-esperjenza ta' wara t-tqegħid fis-suq.
English: Do not take Riprazo HCT - if you are allergic (hypersensitive) to aliskiren or hydrochlorothiazide, to sulphonamide-derived medicines (medicines used to treat chest or urinary infections) or to any of the other ingredients of Riprazo HCT.
Maltese: Tieħux Riprazo HCT - jekk inti allerġiku/a (tbati minn sensittività eċċessiva) għal aliskiren jew hydrochlorothiazide, derivati ta' sulphonamide (mediċini li jintużaw għal-kura ta' infezzjonijiet fis-sider jew talawrina) jew sustanzi oħra ta' Riprazo HCT.
English: Riprazo HCT 300 mg/12.5 mg film-coated tablets
Maltese: Riprazo HCT 300 mg/12.5 mg pilloli miksijin b'rita
English: Medicinal products affecting serum sodium level: The hyponatraemic effect of diuretics may be intensified by concomitant administration of medicinal products such as antidepressants, antipsychotics, antiepileptics, etc.
Maltese: L-effett iponatremiku tad-dijuretiċi jista' jitqawwa bl-għoti flimkien ta' prodotti mediċinali bħal antidipressanti, antipsikotiċi, antiepliettiċi, u l-bqija.
English: Although this has not been investigated for aliskiren, it is known that P-gp also controls tissue uptake of a variety of substrates and P-gp inhibitors can increase the tissue-to-plasma concentration ratios.
Maltese: Għalkemm din ma ġietx investigata għal aliskiren, huwa magħruf li P-gp jikkontrolla wkoll it-teħid ta' varjetà ta' sottostrati mit-tessuti u inibituri ta' P-gp jistgħu jżidu l-proporzjon talkonċentrazzjoni tat-tessuti mal-plażma.
English: Other substances that act directly on the RAAS have been associated with serious foetal malformations and neonatal death when used during second and third trimesters.
Maltese: Sustanzi oħra li jaħdmu direttament fuq RAAS kienu assoċjati ma' malformazzjonijiet tal-feti u mwiet tal-frieħ meta intużaw waqt it-tieni u t-tielet trimestru.
English: Riprazo HCT 150 mg/25 mg film-coated tablets are pale yellow, oval film-coated tablets imprinted with “CLL” on one side and “NVR” on the other.
Maltese: Riprazo HCT 150 mg/25 mg pilloli miksijin b'rita huma pilloli miksijin b'rita jagħtu fl-isfar, ovali stampati b' “CLL” fuq naħa u “NVR” fuq l-oħra.
English: Violet white, biconvex, ovaloid film-coated tablet imprinted with “CVI” on one side and “NVR” on the other.
Maltese: Pillola safra ċara, konvessa miż-żewġ naħat, b'għamla ovali miksija b'rita stampata b' “CVV” fuq naħa u “NVR” fuq l-oħra.
English: Antidiabetic agents (e.g. insulin and oral antidiabetic agents): Thiazides may alter glucose tolerance.
Maltese: Aġenti antidijabetiċi (eż. insulina u sustanzi antidijabetiċi mill-ħalq):
English: Metabolism and nutrition disorders Very common:
Maltese: Sensittività eċċessiva Disturbi tal-metaboliżmu u n-nutrizzjoni Komuni ħafna:
English: Thiazides reduce urinary calcium excretion and may cause an intermittent and slight elevation of serum calcium in the absence of known disorders of calcium metabolism.
Maltese: Thiazides inaqqsu t-tneħħija tal-kalċju mal-awrina u jistgħu jikkawżaw livelli ogħla b'mod intermittenti u ħafif tal-kalċju fis-serum fin-nuqqas ta' disturbi magħrufa ta' metaboliżmu tal-kalċju.
English: • Allergic reactions (hypersensitivity) and angioedema (the symptoms of which can include difficulties in breathing or swallowing, rash, itching, hives or swelling of the face, hands and feet, eyes, lips and/or tongue, dizziness)
Maltese: • Reazzjonijiet allerġiċi (sensittività eċċessiva) u anġjoedima (is-sintomi tagħha jistgħu jinkludu diffikultà biex tieħu n-nifs jew biex tibla', raxx, ħakk, ħorriqija jew nefħa fil-wiċċ, fl-idejn u fis-saqajn, fl-għajnejn, fix-xofftejn u/jew fl-ilsien, sturdament)
English: Iomeprol - Haemolysis (EPITT no 18625)
Maltese: Iomeprol - Emolisi (EPITT nru 18625)
English: Corticosteroids including betamethasone, budesonide, fluticasone, mometasone, prednisone, triamcinolone.
Maltese: Kortikosterojdi inklużi betamethasone, budesonide, fluticasone, mometasone, prednisone, triamcinolone.
English: Corticosteroids primarily metabolised by CYP3A (including betamethasone, budesonide, fluticasone, mometasone, prednisone, triamcinolone).
Maltese: Kortikosterojdi primarjament metabolizzati minn CYP3A (inklużi betamethasone, budesonide, fluticasone, mometasone, prednisone, triamcinolone).
English: Agomelatine - Urinary retention (EPITT no 18637)
Maltese: Agomelatine - Żamma tal-awrina (EPITT nru 18637)
English: Cobicistat containing products: cobicistat; cobicistat, atazanavir sulfate; cobicistat, darunavir; cobicistat, elvitegravir, emtricitabine, tenofovir alafenamide; cobicistat, elvitegravir, emtricitabine, tenofovir disoproxil fumarateDrug interaction with corticosteroids leading to adrenal suppression (EPITT no 18647)
Maltese: 3. Prodotti li fihom cobicistat; cobicistat, atazanavir sulfate; cobicistat, darunavir; cobicistat, elvitegravir, emtricitabine, tenofovir alafenamide; cobicistat, elvitegravir, emtricitabine, tenofovir disoproxil fumarate - Interazzjoni tal-mediċini ma' kortikosterojdi li twassal għal suppressjoni adrenali (EPITT Nru 18647)
English: For Victrelis, Sovaldi, Harvoni, Daklinza, Zepatier and Epclusa (products for which pharmacokinetic studies with warfarin have not been performed)
Maltese: Għal Victrelis, Sovaldi, Harvoni, Daklinza, Zepatier u Epclusa (prodotti li għalihom l-istudji farmakokinetiċi b'warfarin ma twettqux)
English: Boceprevir ; daclatasvir; dasabuvir; elbasvir, grazoprevir; ledipasvir, sofosbuvir; ombitasvir, paritaprevir, ritonavir; simeprevir; sofosbuvir; sofosbuvir, velpatasvir - Drug interaction between direct-acting antivirals (DAAV) and vitamin K antagonists leading to a reduced international normalised ratio (INR) (EPITT no 18654)
Maltese: Boceprevir; daclatasvir; dasabuvir; elbasvir, grazoprevir; ledipasvir, sofosbuvir; ombitasvir, paritaprevir, ritonavir; simeprevir; sofosbuvir; sofosbuvir, velpatasvir - Interazzjoni tal-mediċini bejn antivirali li jaġixxu b'mod dirett (DAAV) u antagonisti tal-vitamina K li jwasslu għal proporzjon normalizzat internazzjonali (INR) imnaqqas (EPITT nru
English: Adopted at the 30 August-2 September 2016 PRAC
Maltese: Adottati fil-PRAC ta' bejn it-30 ta' Awwissu-2 ta' Settembru 2016
English: Cases of Cushing's syndrome and adrenal suppression have been reported.
Maltese: Ġew irrappurtati każijiet ta' sindrome ta' Cushing u ta' suppressjoni adrenali.
English: Undesirable effects
Maltese: 4 - Effetti sekondarji possibbli
English: Co-treatment with CYP3A inhibitors, including cobicistat-containing products, is expected to increase the risk of systemic side-effects.
Maltese: Il-kura flimkien ma' inibituri ta' CYP3A inklużi prodotti li fihom cobicistat, hija mistennija li żżid ir-riskju ta' effetti sekondarji sistematiċi.
English: Frequency “rare”: Inability to completely empty the bladder
Maltese: Frekwenza "rari": Inabilità biex il-borża tal-awrina titbattal kompletament
English: Undesirable effects Renal and urinary disorders Frequency “rare”: Urinary retention
Maltese: Effetti mhux mixtieqa Disturbi fil-kliewi u fis-sistema urinarja Frekwenza "rari":
English: N.B: For Evotaz, Section 4.4 warning should be maintained.
Maltese: N.B: Għal Evotaz, it-twissija ta' Sezzjoni 4.4 għandha tinżamm.
English: Interaction with other medicinal products and other forms of interaction Patients treated with vitamin K antagonists:
Maltese: Interazzjoni ma' prodotti mediċinali oħra u forom oħra ta' interazzjoni Pazjenti kkurati b'antagonisti tal-vitamina K:
English: Summary of product characteristics of cobicistat containing products
Maltese: Sommarju tal-karatteristiċi tal-prodott ta' prodotti li fihom cobicistat
English: For Olysio, Viekirax and Exviera (products for which pharmacokinetic studies with warfarin have been performed)
Maltese: Għal Olysio, Viekirax u Exviera (prodotti li għalihom twettqu studji farmakokinetiċi b'warfarin) Warfarin u antagonisti oħra talvitamina K
English: Interaction with other medicinal products and other forms of interaction
Maltese: Interazzjoni ma' prodotti mediċinali oħrajn u forom oħra ta' interazzjoni
English: Blood and lymphatic system disorders (frequency not known): Haemolytic anaemia
Maltese: Disturbi tad-demm u tas-sistema limfatika (frekwenza mhux magħrufa):
English: Special warnings and precautions for use or 4.5.
Maltese: Twissijiet speċjali u prekawzjonijiet għall-użu jew 4.5.
English: Summary of product characteristics of corticosteroids (excluding topical formulations)
Maltese: Sommarju tal-karatteristiċi tal-prodott tal-kortikosterojdi (esklużi formulazzjonijiet topiċi) 4.4.
English: Frequency not known
Maltese: Żamma tal-awrina
English: While no change in the pharmacokinetics of warfarin is expected, close monitoring of INR is recommended with all vitamin K antagonists.
Maltese: Warfarin u mediċini oħra simili msejħa antagonisiti tal-vitamina K użati biex iraqqu d-demm.
English: 2 - What you need to know before you take {product name}
Maltese: 2 - X'għandek tkun taf qabel tieħu {isem tal-prodott}
English: Concomitant use of <product name> and corticosteroids that are metabolised by CYP3A (e.g. fluticasone propionate or other inhaled or nasal corticosteroids) may increase the risk of development of systemic corticosteroid effects, including Cushing's syndrome and adrenal suppression
Maltese: L-użu fl-istess ħin ta' <isem talprodott> u kortikosterojdi li huma metabolizzati minn CYP3A eż fluticasone propionate jew kortikosterojdi oħra li jinġibdu man-nifs jew nażali jista' jżid ir-riskju tal-iżvilupp ta' effetti sistemiċi talkortikosterojdi, inkluż issindrome ta' Cushing u ssuppressjoni adrenali
English: Haemolytic anaemia (abnormal breakdown of red blood cells, which may cause fatigue, rapid heart rate and shortness of breath)
Maltese: Anemija emolitika (tkissir anormali ta' ċelluli tad-demm ħomor, li jista' jikkawża għeja, taħbit mgħaġġel tal-qalb u qtugħ ta' nifs)
English: France/ Luxembourg/ Portugal/ Italy/ Sweden/ Finland/ Czech Republic/ Slovakia/ Hongary/ Bulgaria/ Romania/ Croatia/ Slovenia/ Republic of Cyprus/ Denmark/ Estonia/ Latvia/ Lithuania/ Malta:
Maltese: Franza / Lussemburgu / Portugall / Italja / Svezja / Finlandja / Repubblika Ċeka / Slovakkja / Ħongar / Bulgarija / Rumanija / Kroazja / Slovenja / Repubblika ta 'Ċipru / Danimarka / Estonja / Latvja / Litwanja / Malta:
English: (See section “Adverse reactions”.)
Maltese: (Ara sezzjoni “Reazzjonijiet avversi”.)
English: ATCvet code: QJ02AC02.
Maltese: QJ02AC02.
English: Duggan Veterinary Supplies Ltd. Holycross
Maltese: Duggan Supplies Veterinarji Ltd Holycross
English: Dechra Veterinary Products GmbH-Austria Hintere Achmühlerstraße 1A 6850 Dornbirn
Maltese: Dechra Veterinary Products GmbH-Awstrija Hintere Achmühlerstraße 1A 6850
English: Psittaciformes, Falconiformes, Accipitriformes, Strigiformes, and Anseriformes:
Maltese: Psittaciformi, Falkoniformi, Aċċipitriformi, Strigiformi, u Anseriformi:
English: Hydroxypropylbetadex Caramel flavour
Maltese: Hydroxypropylbetadex Togħma ta' karamella
English: Mascotasana s.a. Poima 26
Maltese: Mascotasana s.a.
English: Psittaciformes (specifically cockatoos and true parrots: parakeets; budgerigars) Falconiformes (falcons)
Maltese: Psittaciformi (speċifikament kakatuwi u pappagalli veri: parrukketti; amorini) Falkoniformi (falkuni)
English: 10 ml including oral syringe 50 ml including oral syringe
Maltese: 10 ml inkluża siringa orali 50 ml inkluża siringa orali
English: Unit 2, 2 Cavendish Rd Bury Saint Edmunds IP33 3TE Tel.: 0044-1284761131
Maltese: Petlife International Ltd Unità 2, 2 Cavendish Rd Bury Saint Edmunds IP33 3TE Tel .: 0044-1284761131
English: Active substance: Itraconazole
Maltese: Itraconazole